Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
NewLimit has raised $435 million and accelerated its lead epigenetic reprogramming therapy into human trials next year—a timeline compressed from over a decade away due to unexpectedly compelling preclinical data in liver cells. The approach targets aging at the cellular level to restore function rather than halt time, positioning epigenetic intervention as a potential foundation for addressing multiple age-related diseases simultaneously.
InsideTracker launched Terra, an AI platform that integrates wearable data, blood biomarkers, and health apps to deliver personalized recommendations for wellness and healthcare businesses. The shift reflects growing consumer demand for evidence-based outcomes rather than generic wellness claims, reshaping how the industry validates health interventions.
Elecoglipron (AZD5004/ECC5004), an oral once-daily GLP-1 receptor agonist developed by Eccogene and AstraZeneca, will present Phase 1b and Phase 2b clinical trial data at the American Diabetes Association Scientific Sessions in June 2026. The candidate targets weight loss and type 2 diabetes management with the practical advantage of no food or water restrictions.
Augustine Therapeutics will present preclinical data on an HDAC6 inhibitor for heart failure with preserved ejection fraction at the American Diabetes Association conference. The selective HDAC6 inhibitor represents a mechanistic approach to a prevalent cardiometabolic phenotype where ejection fraction remains normal despite functional impairment.
Handgrip strength significantly moderates the relationship between depression and cancer risk in adults over 50, with stronger grip associated with reduced cancer incidence across multiple cancer types. This finding suggests that neuromuscular capacity functions as a protective factor against the compounding effects of depression on malignant disease.
Fractyl Health has initiated the first human trial of RJVA-001, a gene therapy designed to enable the pancreas to produce GLP-1 endogenously rather than requiring chronic external dosing. This approach represents a fundamental shift in metabolic medicine from lifelong symptom management toward potential restoration of underlying physiological function.
Kailera Therapeutics is advancing ribupatide injection (KAI-9531), a once-weekly GLP-1/GIP dual agonist in Phase 3 trials for obesity treatment, with company leadership presenting clinical updates at the June 2026 Jefferies conference. The candidate represents one of several GLP-1-based mechanisms in development aimed at addressing weight regulation across different patient populations and delivery preferences.
Mayrlife Medical Health Resort has developed a structured lifestyle integration program for individuals already using GLP-1 medications, combining personalized nutrition, movement conditioning, and recovery protocols to address the metabolic and compositional changes that occur during pharmacologically-assisted weight loss. The program targets a critical gap: sustaining weight loss outcomes and preserving lean mass after GLP-1 initiation, rather than treating medication use in isolation.
Junevity's siRNA therapeutic demonstrates the ability to restore dysregulated gene networks to baseline function in diabetic models, with durable target knockdown and no safety signals in preclinical studies. This represents a shift from symptomatic management toward correcting upstream transcriptional dysfunction that drives metabolic and neurodegenerative disease.
Early-onset time-restricted feeding improved healthspan markers in both male and female mice on standard diet, though lifespan extension occurred only in males. This sex-differentiated response suggests that feeding timing influences aging trajectories through mechanisms that operate independently in males and females.
Five finalists selected for The Longevity Show's inaugural pitch competition represent a conceptual shift in the longevity sector—from single-intervention therapies to integrated systems spanning therapeutics, nutrition, microbiome science, and healthcare access. The cohort signals movement toward infrastructure that supports healthspan across diverse populations and geographies.
Elysium Health is launching a physician-led longevity care program combining personalized supplements, prescriptions, peptides, and clinical monitoring — signaling a broader industry shift from isolated consumer products toward integrated healthcare delivery models. The structural evolution reflects market maturation and consumer demand for coordinated interventions rather than fragmented wellness tools.